



Erratum

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

D. B. PRICE, R. H. BEN-JOSEPH AND Q. ZHANG

RESPIRATORY MEDICINE (2001) 95, 83–89

It is regretted that in the above article, table 3 was printed incorrectly. The correct table follows below.

TABLE 3. Asthma therapy cost and utilization changes among patients using chronic montelukast therapy and patients with chronic salmeterol and concomitant ICS use before and after IPD

	Montelukast			Salmeterol		
	Before IPD [†] <i>n</i> = 49	After IPD [†] <i>n</i> = 49	Change [‡]	Before IPD [†] <i>n</i> = 49	After IPD [†] <i>n</i> = 49	Change [‡]
Monthly cost (£) mean ± SD						
ICS	19.96 ± 24.96	17.56 ± 20.53	-2.40 ± 17.54	11.94 ± 17.99	25.24 ± 20.08	13.30* ± 20.25
Long-acting β-agonist	10.50 ± 15.31	10.90 ± 16.23	0.40 ± 12.46	0.48 ± 3.39	30.93 ± 9.51	30.45 ± 10.03
Short-acting β-agonist	4.66 ± 9.68	2.93 ± 5.62	-1.73* ± 5.74	2.71 ± 7.94	2.97 ± 7.64	0.26 ± 2.86
Antibiotics	2.19 ± 3.73	1.04 ± 1.55	-1.15* ± 3.89	1.44 ± 5.69	1.98 ± 8.10	0.54 ± 7.53
Total non-montelukast	37.31 ± 37.94	32.43 ± 28.79	-4.88 ± 25.78	16.57 ± 30.65	61.12 ± 31.44	44.55* ± 3.95
Montelukast	0	27.64 ± 4.87	27.64 ± 4.87	0	0	0
Total monthly drug costs	37.31 ± 37.94	60.07 ± 29.51	22.76* ± 26.09	16.57 ± 30.65	61.12 ± 31.44	44* ± 55 ± 3.95
Packs prescribed [¶]						
Short-acting β-agonists	0.88 ± 1.03	0.70 ± 0.93	-20%	0.81 ± 1.69	0.81 ± 1.32	- <0.5%
Antibiotics	0.21 ± 0.28	0.12 ± 0.18	-43%*	0.15 ± 0.15	0.35 ± 1.83	133%
Oral steroids	0.8 ± 0.12	0.06 ± 0.16	-25%	0.05 ± 0.09	0.05 ± 0.14	2%

*Change is statistically significant ($P < 0.05$).

[†]Index Prescription Date.

[‡]Change from before index prescription date to after index prescription date.

[¶]Change in number of packs prescribed (after index prescription date minus before index prescription date), expressed as a percentage of packs prescribed before index prescription date.